Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

NACompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
HIV Infection
Interventions
DIETARY_SUPPLEMENT

Vitamin D3 50,000 IU

Group A: Vitamin D3 50,000 IU orally every four weeks by DOT

DIETARY_SUPPLEMENT

Vitamin D3 placebo

Group B: Vitamin D3 placebo orally every four weeks by DOT

Trial Locations (17)

10467

Montefiore Medical Center, The Bronx

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Childrens National Medical Center, Washington D.C.

21287

Johns Hopkins University - NICHD Westat Site, Baltimore

Johns Hopkins University, Baltimore

33101

University of Miami School of Medicine, Miami

33316

Children's Diagnostic and Treatment Center - NICHD Westat Site, Fort Lauderdale

33606

University of South Florida, Tampa

38105

St. Jude Childrens Research Hospital, Memphis

48201

Wayne State University, Detroit

60612

Stroger Hospital and the CORE Center, Chicago

70112

Tulane Medical Center, New Orleans

77030

Baylor College of Medicine, Houston

90027

Children's Hopsital of Los Angeles, Los Angeles

90033

University of Southern California - NICHD Westat Site, Los Angeles

02215

Fenway Institute, Boston

00936-5067

San Juan City Hospital (Puerto Rico) - NICHD Westat Site, San Juan

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT01751646 - Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART | Biotech Hunter | Biotech Hunter